SecBot SecBot
8-K ·Filed Jul 29, 2026

ANIK

Anika Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0001171843-26-004977
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The magnitude of the beat and guidance raise is significant for a $202M market cap stock. The removal of Hyalofast from 2027 guidance introduces a binary catalyst risk (FDA PMA decision) that could drive the next leg. Traders should monitor the Q3 earnings call for updates on Hyalofast PMA discussions and Cingal NDA timeline, as positive regulatory news would remove the primary overhang on the 2027 outlook.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ANIK drug pipeline →

CINGAL

● Neutral Named in this 8-K
Impact
Phase
Pre-NDA (US drug application path; not a standard clinical phase)
Time to market
Unknown, and likely 2027 at the earliest: the NDA had not been confirmed as filed as of mid-2026, and a US approval decision would typically come roughly 10 months after a completed, accepted submission.
Next catalyst
None dated

What to watchWatch Anika's Q3 2026 earnings call (next scheduled update) for a confirmation that the Cingal NDA was formally submitted and for FDA acceptance, that would finally give the stock a dated regulatory clock. Until a submission is confirmed, treat Cingal as a 2027+ US revenue story, not a near-term binary; near-term price action is being driven by the Q2 2026 earnings beat and guidance raise rather than by Cingal news.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.17
T+0 close · Jul 29, 2026 · via day close
Latest settled
+30.43%
T+60 · $21.09
Vs SPY
+25.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $16.17entry
  2. T+1 · 4mo ago +11.75%α +10.07% · $18.07
  3. T+5 · 3mo ago +18.68%α +13.15% · $19.19
  4. T+20 · 3mo ago +34.08%α +29.06% · $21.68
  5. T+60 · 26d ago +30.43%α +25.70% · $21.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03 consensus) and revenue of $32.6M (vs $29.2M consensus), driven by record Commercial Channel revenue of $13.9M (+17% YoY) and gross margin expansion to 65%. The company raised full-year 2026 guidance across all metrics, most notably lifting adjusted EBITDA margin guidance from 5%-10% to 13%-17%, signaling a structural profitability inflection. The bullish read is tempered by the removal of Hyalofast revenue from 2027 guidance due to FDA timing uncertainty, but the magnitude of the beat and guidance raise dominates the narrative for a $202M market cap stock.

Key Financial Metrics

EPS
$0.24
est $0.03 · +700.0%
Revenue
$32.6M
est $29.2M · +11.7% · +15.6% YoY
Rating
strong beat
Guidance
5% to 10% growth (implied ~$117M-$123M)
raised
Free Cash Flow
-$8.4M
Gross Margin
65.1%

Key Facts

  • Q2 2026 revenue $32.6M, up 16% YoY vs $28.2M, beating $29.2M consensus
  • GAAP diluted EPS $0.24 vs consensus $0.03 (700% beat); adjusted diluted EPS $0.42
  • Gross margin expanded to 65% from 51% in Q2 2025, driven by volume and mix
  • Adjusted EBITDA $7.1M (22% margin), highest since 2020, vs -$0.2M in Q2 2025
  • Raised FY2026 guidance: total revenue growth 5%-10% (prev. 1%-9%), adj. EBITDA margin 13%-17% (prev. 5%-10%)
  • Commercial Channel revenue hit record $13.9M, +17% YoY; International revenue record $12.6M, +22% YoY
  • Removed Hyalofast revenue from 2027 guidance due to FDA timing uncertainty; new policy: forecast only approved products
  • Cash and equivalents $38.4M as of June 30, 2026, down from $57.5M at Dec 2025 due to share repurchases and inventory build

Financial Impact

Q2 revenue beat consensus by $3.4M (11.6%); GAAP EPS beat by $0.21 (700%); FY2026 EBITDA margin guidance raised from 5-10% to 13-17%, implying ~$7-10M incremental EBITDA on ~$120M revenue

revenueepsgross marginadjusted ebitdaguidance

Risk Factors

  • Hyalofast PMA uncertainty: FDA deficiency letter and removal from 2027 guidance creates binary outcome risk
  • Cash burn: operating cash flow -$5.5M YTD and cash down $19M from Dec 2025 due to share repurchases and inventory build
  • Second-half moderation expected: management guided for slower H2 vs H1 due to OEM order timing
  • Small analyst coverage (1 analyst) limits institutional visibility and liquidity

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-004977
Document: f8k_072926.htm0001171843-26-004977
Document: 0001171843-26-004977-index-headers.html0001171843-26-004977
Document: 0001171843-26-004977-index.html0001171843-26-004977
Document: 0001171843-26-004977.txt0001171843-26-004977
8-K Data (Synthetic)0001171843-26-004977

Track record

13 reports on ANIK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
  2. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
  3. Jul 29, 202615w ago 8-K Bullish 8/10 Viewing Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
  4. Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
  7. Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
  8. Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
  9. Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
  10. Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 5h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026